MCID: MMB011
MIFTS: 55

Membranous Nephropathy

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 53 12 49 28
Membranous Glomerulonephritis 12 49 14 69
Membranous Nephropathy, Susceptibility to 53 13
Idiopathic Membranous Glomerulonephritis 55 69
Idiopathic Membranous Nephropathy 49 51
Glomerulonephritis, Membranous 49 41
Extramembranous Glomerulonephritis 49
Nephropathy Membranous 51
Membranous Gn 49
Mbnp 53
Mgn 49

Classifications:

Orphanet: 55  
Rare renal diseases


External Ids:

OMIM 53 614692
Disease Ontology 12 DOID:10976
ICD10 32 N03.2
MeSH 41 D015433
NCIt 46 C34645
SNOMED-CT 64 197710000 77182004
Orphanet 55 ORPHA97560
UMLS via Orphanet 70 C0086445
ICD10 via Orphanet 33 N04.2

Summaries for Membranous Nephropathy

OMIM : 53 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to focal segmental glomerulosclerosis 1 and nephrotic syndrome. An important gene associated with Membranous Nephropathy is MBNP (?Membranous Nephropathy, Susceptibility To), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Angiotensin II and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and neutrophil, and related phenotypes are homeostasis/metabolism and renal/urinary system

NIH Rare Diseases : 49 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause of membranous nephropathy is not known. Some cases are associated with other conditions (lupus), infections (hepatitis B and C), cancer or as a side effect of certain medications. The goal of treatment is to reduce symptoms and slow the progression of the disease.  Last updated: 9/2/2014

Wikipedia : 72 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Maternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 focal segmental glomerulosclerosis 1 30.4 CD2AP NPHS1 NPHS2
2 nephrotic syndrome 30.4 ALB CD2AP NPHS1 NPHS2
3 interstitial nephritis 30.3 ACE ALB TINAG
4 membranoproliferative glomerulonephritis 30.0 ALB CD79A NPHS1
5 glomerulonephritis 29.7 ALB CD79A LRP2 NPHS1 NPHS2
6 chronic graft versus host disease 29.7 ALB CD79A
7 focal segmental glomerulosclerosis 29.7 ACE ALB CD2AP NPHS1 NPHS2
8 microvascular complications of diabetes 3 29.6 ACE ALB NPHS1
9 kidney disease 29.0 ACE ALB CD2AP NPHS1 NPHS2
10 iga glomerulonephritis 28.6 ACE ALB CD2AP CD79A NPHS1 NPHS2
11 alport syndrome and thin basement membrane nephropathy 12.2
12 anti-basement membrane glomerulonephritis 12.1
13 congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization 12.0
14 hematuria, benign familial 11.9
15 goodpasture syndrome 11.1
16 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 10.5 NPHS1 NPHS2
17 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.4 CD2AP NPHS2
18 hypoparathyroidism, sensorineural deafness, and renal disease 10.4 NPHS1 NPHS2
19 cork-handlers' disease 10.3 ALB CD79A
20 ostertagiasis 10.3 ALB CD79A
21 kidney hypertrophy 10.3 ALB NPHS1 NPHS2
22 dermatitis, atopic, 3 10.3 ALB CD79A
23 atrial septal defect 3 10.3 CD2AP NPHS1 NPHS2
24 familial nephrotic syndrome 10.3 CD2AP NPHS1 NPHS2
25 nephrotic syndrome, type 1 10.2 CD2AP NPHS1 NPHS2
26 root caries 10.2 ALB CD79A
27 denys-drash syndrome 10.2 CD2AP NPHS1 NPHS2
28 marasmus 10.2 ALB CD79A
29 frasier syndrome 10.2 CD2AP NPHS1 NPHS2
30 parotitis 10.2 ALB CD79A
31 yellow nail syndrome 10.2 ALB CD79A
32 congenital toxoplasmosis 10.2 CD79A HLA-DQA1
33 hypertensive nephropathy 10.2 ACE ALB
34 syndrome of inappropriate antidiuretic hormone 10.2 ACE ALB
35 diffuse glomerulonephritis 10.2 ALB CD79A
36 anuria 10.2 ACE ALB
37 focal dermal hypoplasia 10.2 ALB CD79A
38 alport syndrome, x-linked 10.1
39 hepatitis 10.1
40 non-secretory myeloma 10.1 ALB CD79A
41 testicular torsion 10.1 ACE CD79A
42 erythema elevatum diutinum 10.1 CD79A PECAM1
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
44 hepatitis b 10.1
45 celiac disease 1 10.0 ALB CD79A HLA-DQA1
46 hypersensitivity reaction type iii disease 10.0 ALB CD79A
47 precursor t-lymphoblastic lymphoma/leukemia 10.0 CD79A MME
48 orthostatic proteinuria 10.0 ACE ALB CD79A
49 encapsulated thymoma 10.0 CD79A MME
50 precursor lymphoblastic lymphoma/leukemia 10.0 CD79A MME

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

MGI Mouse Phenotypes related to Membranous Nephropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 CD79A LRP2 LRPAP1 MME NPHS1 NPHS2
2 renal/urinary system MP:0005367 9.28 ACE ALB CD2AP CD79A LRP2 LRPAP1

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
5
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
8 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
9 Hormones Phase 4,Phase 2,Phase 3,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
11 Angiotensin II Type 1 Receptor Blockers Phase 4
12 Angiotensin Receptor Antagonists Phase 4,Phase 3
13 Angiotensinogen Phase 4,Phase 3
14 Antihypertensive Agents Phase 4
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
16 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
17 Antifungal Agents Phase 4,Phase 3,Phase 2
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
20 Antitubercular Agents Phase 4,Phase 3,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
22 Cyclosporins Phase 4,Phase 3,Phase 2
23 Dermatologic Agents Phase 4,Phase 3,Phase 2
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
25 Adrenocorticotropic Hormone Phase 4,Phase 2,Phase 1
26 beta-endorphin Phase 4,Phase 2,Phase 1
27 Melanocyte-Stimulating Hormones Phase 4,Phase 2,Phase 1
28 Immunoglobulin A Phase 4,Phase 2
29 Antiviral Agents Phase 4,Phase 1,Phase 2
30 Endorphins Phase 4
31 Neurotransmitter Agents Phase 4,Phase 3
32 Tripterygium Nutraceutical Phase 4
33 Deflazacort Approved, Investigational Phase 3 14484-47-0
34
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
36
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
37
rituximab Approved Phase 2, Phase 3, Early Phase 1 174722-31-7 10201696
38
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
39
Chlorambucil Approved Phase 3 305-03-3 2708
40 Methylprednisolone acetate Phase 3,Phase 2
41 Methylprednisolone Hemisuccinate Phase 3,Phase 2
42 Prednisolone acetate Phase 3,Phase 2
43 Prednisolone hemisuccinate Phase 3,Phase 2
44 Prednisolone phosphate Phase 3,Phase 2
45 Antiemetics Phase 2, Phase 3
46 Anti-Inflammatory Agents Phase 2, Phase 3
47 Autonomic Agents Phase 2, Phase 3
48 Gastrointestinal Agents Phase 2, Phase 3
49 glucocorticoids Phase 2, Phase 3
50 Neuroprotective Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 66)

# Name Status NCT ID Phase Drugs
1 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
2 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
3 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
4 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
5 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
6 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
7 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
8 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
9 Acthar for Treatment of Post-transplant FSGS Not yet recruiting NCT02399462 Phase 4 Acthar
10 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
11 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
12 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
13 Mycophenolate Mofetil in Membranous Nephropathy Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
14 Treatment of Patients With Idiopathic Membranous Nephropathy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
15 Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
16 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
17 A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
18 Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Recruiting NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
19 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
20 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Active, not recruiting NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
21 MEmbranous Nephropathy Trial Of Rituximab Active, not recruiting NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
22 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Active, not recruiting NCT02077868 Phase 3 MGN1703 treatment
23 A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
24 Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy Completed NCT00694863 Phase 2 tetracosactide hexacetaat
25 Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC Completed NCT02200081 Phase 2 MGN1703
26 Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
27 Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma Completed NCT01208194 Phase 2 MGN1703;Placebo
28 A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
29 Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection Completed NCT02443935 Phase 1, Phase 2 MGN1703;MGN1703
30 Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV Completed NCT02690103 Phase 2 pegylated IFN;Ribavirin
31 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
32 Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy Recruiting NCT03255447 Phase 2
33 Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN) Recruiting NCT03285711 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
34 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
35 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Recruiting NCT02682407 Phase 2
36 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Recruiting NCT03453619 Phase 2 APL-2
37 A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) Active, not recruiting NCT01265368 Phase 1, Phase 2
38 Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
39 A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 Completed NCT01982747 Phase 1 MGN-Placebo;Placebo-MGN
40 Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed NCT00805753 Phase 1 ACTH
41 Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Recruiting NCT02668770 Phase 1 MGN1703;Ipilimumab
42 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Recruiting NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
43 Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
44 Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy Unknown status NCT01845688 Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule
45 Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy Unknown status NCT01799460 The Comprehensive Treatment Regimen of Traditional Chinese Medicine;The immunosuppressive agents
46 Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation Unknown status NCT01897961
47 Study on the Therapeutic Effect of TCM Treatment for MDR MN Unknown status NCT02610595 Jianpixiaozhong particles and Wuse Dietotherapy
48 Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization Unknown status NCT00199628
49 Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies Unknown status NCT00456118
50 The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy Completed NCT00983034 lansoprazole, amoxicillin, clarithromycin

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 28

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

38
Kidney, Bone, Neutrophil, Endothelial, T Cells, Thyroid, Bone Marrow

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 879)
# Title Authors Year
1
Anti-PLA2R antibody in a secondary cause of membranous nephropathy. ( 29250915 )
2018
2
Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report. ( 29349731 )
2018
3
Urine proteomics of primary membranous nephropathy using nanoscale liquid chromatography tandem mass spectrometry analysis. ( 29445323 )
2018
4
The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. ( 29441742 )
2018
5
BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. ( 29423047 )
2018
6
Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy. ( 29416596 )
2018
7
Mannose-Binding Lectin2 Gene Polymorphism and IgG4 in Membranous Nephropathy. ( 29439276 )
2018
8
The skin-kidney connection: bullous pemphigoid associated with acute allograft rejection and membranous nephropathy. ( 29445491 )
2018
9
Membranous glomerulonephritis with an LMNA mutation. ( 29349732 )
2018
10
Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy. ( 29423201 )
2018
11
Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary! ( 29423200 )
2018
12
Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy. ( 29340324 )
2018
13
High urinary interleukin-8 levels is associated with poor prognosis in idiopathic membranous nephropathy. ( 29415357 )
2018
14
The clinicopathological features of patients with membranous nephropathy. ( 29403303 )
2018
15
Management of Membranous Nephropathy in the PLA<sub>2</sub>R Era. ( 29378770 )
2018
16
Combined membranous nephropathy and tubulointerstitial nephritis as a rare renal manifestation of IgG4-related disease: a case-based literature review. ( 29388171 )
2018
17
(5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating FcI^ receptor signaling. ( 28880016 )
2017
18
Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. ( 28852480 )
2017
19
Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. ( 28882100 )
2017
20
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. ( 28090051 )
2017
21
Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy. ( 28935926 )
2017
22
Pre- and Posttransplant Refractory Idiopathic Membranous Glomerulonephritis: The Forgotten Potential Culprit. ( 28847264 )
2017
23
A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. ( 28814510 )
2017
24
Secondary Syphilis Associated with Membranous Nephropathy and Acute Hepatitis in a Patient with HIV: A Case Report. ( 29236656 )
2017
25
Circulating antibodies to I+-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. ( 26830547 )
2017
26
Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. ( 28056860 )
2017
27
Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy. ( 28904360 )
2017
28
Membranous nephropathy: integrating basic science into improved clinical management. ( 28065518 )
2017
29
Inhibition of tumor necrosis factor signaling attenuates renal immune cell infiltration in experimental membranous nephropathy. ( 29340080 )
2017
30
A comprehensive narrative review of diagnostic biomarkers in human primary membranous nephropathy. ( 28891307 )
2017
31
Value of immunofluorescence-mediated detection of Ig, C1q, C3, and FRA for the identification and diagnosis of atypical membranous nephropathy. ( 29243784 )
2017
32
Treatment of primary membranous nephropathy: where are we now? ( 28875476 )
2017
33
Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting. ( 28904444 )
2017
34
Blockage of the lysosome-dependent autophagic pathway contributes to complement membrane attack complex-induced podocyte injury in idiopathic membranous nephropathy. ( 28819100 )
2017
35
Hypocomplementemic Urticarial Vasculitis Syndrome with Membranous Nephropathy: Case Report. ( 29115092 )
2017
36
Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy. ( 28904948 )
2017
37
Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy. ( 28944778 )
2017
38
Translational Aspects of Primary Membranous Nephropathy. ( 28863791 )
2017
39
Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. ( 28084563 )
2017
40
Risk alleles for IgA nephropathy-associated SNPs conferred completely opposite effects to idiopathic membranous nephropathy in Chinese Han. ( 28929317 )
2017
41
Coexistence of Anti-Glomerular Basement Membrane Glomerulonephritis and Membranous Nephropathy in a Female Patient with Preserved Renal Function. ( 29269610 )
2017
42
Complement System and C4d expression in cases of Membranous nephropathy. ( 29319762 )
2017
43
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. ( 28821362 )
2017
44
Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience. ( 28852884 )
2017
45
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. ( 28257452 )
2017
46
Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases? ( 28245485 )
2017
47
A rare case of concurrent myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated necrotising and crescentic glomerulonephritis and membranous glomerulonephritis. ( 27931720 )
2017
48
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. ( 28898290 )
2017
49
Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy. ( 28849274 )
2017
50
Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents. ( 28877834 )
2017

Variations for Membranous Nephropathy

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

Pathways related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 CD2AP MME NPHS1 NPHS2 VTN
2 10.62 ACE MME
3 10.55 CD2AP NPHS1 NPHS2
4 10.5 CD2AP NPHS1

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 ACE CD2AP CD79A HLA-DQA1 LRP2 LRPAP1
2 endoplasmic reticulum GO:0005783 9.91 ALB HLA-DQA1 LRP2 LRPAP1 NPHS2 VTN
3 lysosome GO:0005764 9.71 ACE HLA-DQA1 LRP2 TINAG
4 external side of plasma membrane GO:0009897 9.62 ACE CD79A LRP2 PECAM1
5 endosome lumen GO:0031904 9.37 LRP2 LRPAP1
6 extracellular exosome GO:0070062 9.36 ACE ALB CD2AP LRP2 MME NPHS1
7 slit diaphragm GO:0036057 9.26 NPHS1 NPHS2
8 rough endoplasmic reticulum lumen GO:0048237 8.96 LRPAP1 VTN

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta metabolic process GO:0050435 9.32 ACE MME
2 replicative senescence GO:0090399 9.26 MME PLA2R1
3 angiotensin maturation GO:0002003 9.16 ACE MME
4 receptor-mediated endocytosis GO:0006898 9.02 ALB LRP2 PLA2R1 TINAG VTN
5 regulation of receptor-mediated endocytosis GO:0048259 8.96 CD2AP LRPAP1

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 9.16 TINAG VTN
2 drug binding GO:0008144 9.13 ACE ALB LRP2
3 exopeptidase activity GO:0008238 8.62 ACE MME

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....